Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTITUDE-1: Cilta-cel in R/R Multiple Myeloma
NCT03548207Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Jun 2018; status: completed.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03548207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548207.